When.com Web Search

  1. Ads

    related to: what is daratumumab prescribed for in dogs side effects long term

Search results

  1. Results From The WOW.Com Content Network
  2. Daratumumab - Wikipedia

    en.wikipedia.org/wiki/Daratumumab

    Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]

  3. List of long term side effects of antipsychotics - Wikipedia

    en.wikipedia.org/wiki/List_of_long_term_side...

    Many patients will not develop these side effects, although there is still a significant possibility of risks associated with Antipsychotic usage. The percentage of patients affected by side effects like Tardive dyskinesia is significantly high and estimated to be a 20-50% prevalence. [1] [2]

  4. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    pain associated with osteoarthritis in dogs [36] Begelomab [6] mab: mouse: DPP4: Belantamab mafodotin [5] Blenrep: mab: humanized: B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma Belimumab [37] Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS ...

  5. Benadryl for Dogs? A Vet Explains How Much You Should Give - AOL

    www.aol.com/lifestyle/benadryl-dogs-vet-explains...

    Dr. Mark explains how to safely sedate a dog with Benadryl by using the correct doses.

  6. List of veterinary drugs - Wikipedia

    en.wikipedia.org/wiki/List_of_veterinary_drugs

    clindamycin – antibiotic with particular use in dental infections with effects against most aerobic Gram-positive cocci, as wel as muchenionoweloozi disorder. clomipramine – primarily used in dogs to treat behavioral problems

  7. Daratumumab/hyaluronidase - Wikipedia

    en.wikipedia.org/wiki/Daratumumab/hyaluronidase

    It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]